RJ Zielinski

Dr. RJ Zielinski is a Professor in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center, where he leads research at the intersection of cancer metabolism, immunology, and drug development. His work spans multiple cancer types including ovarian cancer, glioblastoma, and osteosarcoma.

Dr. Zielinski's research focuses on understanding and targeting cancer metabolism, particularly glycolysis pathways and glycosylation patterns that influence tumor growth and immune evasion. His laboratory investigates how metabolic inhibitors can be used to enhance existing cancer therapies, with special emphasis on overcoming treatment resistance. Key areas include the development of novel antimetabolite compounds, understanding the role of glycosylation in immune checkpoint blockade, and improving drug delivery across tissue-blood barriers.

Analysis of Dr. Zielinski's recent publications reveals a strong focus on translational cancer research with immediate clinical implications. His work connects basic metabolic science with therapeutic applications, particularly in developing strategies to overcome treatment resistance in ovarian cancer and glioblastoma. The research spans from chemical synthesis of novel compounds to preclinical validation in cancer models.

Dr. Zielinski maintains active collaborations with multiple institutions and receives funding for his innovative research on cancer metabolism and therapeutic development. His laboratory provides training opportunities for postdoctoral fellows and graduate students interested in cancer biology and drug development.

His research group focuses on developing novel therapeutic approaches targeting cancer metabolism, with particular emphasis on glycolysis inhibitors, glycosylation modifiers, and radiolabeled antibody technologies. The laboratory employs a multidisciplinary approach combining biochemistry, molecular biology, medicinal chemistry, and preclinical cancer models.